Moderna announced this morning that its COVID19 shots provide strong protection. Moderna said its vaccine appears to be 94.5% effective, according to preliminary data from the company’s still ongoing study. A week ago, competitor Pfizer Inc. announced its own COVID19 vaccine appeared similarly effective — news that puts both companies on track to seek permission within weeks for emergency use in the US. Dr. Stephen Hoge, Moderna’s president, welcomed the “really important milestone” but said having similar results from two different companies is what’s most reassuring.
To read the Moderna media release: CLICK HERE (You will be redirected)
Both vaccine candidates require people to get two shots, several weeks apart. Moderna expects to have about 20 million doses, earmarked for the US., by the end of 2020. Pfizer and its German partner BioNTech expect to have about 50 million doses globally by year’s end. Moderna’s vaccine, created with the National Institutes of Health, is being studied in 30,000 volunteers who received either the real vaccination or a dummy shot. On Sunday, an independent monitoring board broke the code to examine 95 infections that were recorded starting two weeks after volunteers’ second dose — and discovered all but five illnesses occurred in participants who got the placebo.
Contains files from The Associated Press
Photo Credit: Centre for Disease Control
We just announced that mRNA-1273, our COVID-19 vaccine candidate, has met its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study.
Read more: https://t.co/vYWEy8CKCv pic.twitter.com/YuLubU1tlx
— Moderna (@moderna_tx) November 16, 2020
Moderna says its coronavirus vaccine appears to be 94.5% effective, according to preliminary data from the company’s still ongoing study. A week ago, competitor Pfizer Inc. said its own COVID-19 vaccine appeared similarly effective. https://t.co/LJbuupHQE2
— The Associated Press (@AP) November 16, 2020
— Reuters (@Reuters) November 16, 2020